Caris Life Sciences (CAI) Income towards Parent Company (2024 - 2026)

Caris Life Sciences' Income towards Parent Company history runs 3 years deep, the most recent figure standing at -$510000.0 for Q1 2026.

• In Q1 2026, Income towards Parent Company rose 99.5% year-over-year to -$510000.0; the TTM figure through Mar 2026 stood at $34.0 million (up 112.43% YoY), while the FY2025 annual figure was -$68.1 million, up 75.85% from the prior year.
• Income towards Parent Company was -$510000.0 for Q1 2026 at Caris Life Sciences, down from $82.0 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $82.0 million in Q4 2025 to a low of -$102.6 million in Q1 2025.
• Historically, Income towards Parent Company has averaged -$29.9 million across 3 years, with a median of -$51.6 million in 2024.
• Biggest YoY gain for Income towards Parent Company was 321.82% in 2025; the steepest drop was 8.47% in 2025.
• A 3-year view of Income towards Parent Company shows it stood at -$36.9 million in 2024, then soared by 321.82% to $82.0 million in 2025, then sank by 100.62% to -$510000.0 in 2026.
• The last three Income towards Parent Company figures came in at -$510000.0 (Q1 2026), $82.0 million (Q4 2025), and $24.3 million (Q3 2025), per Business Quant data.